Correctly described. To their credit it is definitely not easy to break into big pharma's established workflows. They are participating in industry conferences and setting up stands. In a hindsight, product businesses need small to medium businesses as clients which can be bread and butter while they are trying to break into big businesses. The decision making at that level is not in years and these second tier businesses are constantly looking how to differentiate. This somehow has not happened. Also we have not seen any action to contain the costs in view of slow uptake.
Correctly described. To their credit it is definitely not easy...
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BCT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.616M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 8799208 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 1777333 | 2 |
View Market Depth
| Last trade - 14.18pm 30/09/2024 (20 minute delay) ? |
| BCT (ASX) Chart |
Day chart unavailable